role of leukotriene receptor antagonists in the treatment of exercise-induced bronchoconstriction a review白三烯受体拮抗剂在治疗运动性支气管狭窄审查.pdfVIP

Review Article Role of Leukotriene Receptor Antagonists in the Treatment of Exercise-Induced Bronchoconstriction: A Review George S. Philteos, MD, FRCP(C); Beth E. Davis, BSc; Donald W. Cockcroft, MD, FRCP(C); Darcy D. Marciniuk, MD, FRCP(C) Abstract Asthma is a very common disorder that still causes significant morbidity and mortality. A high percent- age of individuals with asthma also experience exercise-induced bronchoconstriction (EIB). This article reviews the current literature and updates the reader on the safety, efficacy, and clinical applications of leukotriene modifiers in the treatment of EIB. Asthma affects 14 to 15 million people in the tomatic asthma.3,4 This article reviews the cur- United States and is responsible for more than rent literature and updates the reader on the safety, 100 million days of restricted activity, more than efficacy, and clinical applications of leukotriene 5,000 deaths, and 470,000 hospitalizations each modifiers in the treatment of EIB. year.1 Previously characterized as a disease of air- way smooth muscle, asthma is currently defined by the National Heart, Lung, and Blood Institute Role of Leukotrienes in Asthma Pathogenesis as “a chronic inflammatory disorder of the airways in which many cells and cellular elements play a Various biologic signals (including receptor acti- role, in particular, mast cells, eosinophils, T lym- vation, antigen-antibody interaction, and physical phocytes, macrophages, neutrophils, and epithelial stimuli such as cold) activate cytosolic phospho- cells.”2 Exercise-induced bronchoconstriction lipase A2 to liberate arachidonic acid from mem- (EIB) occurs in approximately 80 to 90% of indi- brane phospholipids.5 The liberated arachidonic viduals with asthma and in approximately 11% of acid is then metabolized to va